The Treatment for Perimenopausal Depression
Most Women Are Never Told About

In 2026, the International Federation of Gynecology and Obstetrics - the body representing obstetricians and gynaecologists across more than 140 countries - published its first comprehensive best practice recommendations specifically addressing the mental health of women during the menopausal transition. These guidelines synthesise evidence across 13 clinical questions and represent the strongest international consensus to date on perimenopausal mental health. They shift how the medical community is expected to understand, screen for, and treat mood symptoms during midlife in ways that matter practically for every woman approaching or moving through this stage.

What they confirm is something many women have already lived without being given language for it: perimenopause is a neurobiological event. And the mental health consequences of that event are both common and chronically underrecognised.

How Common Are Mood Symptoms in Perimenopause?

The scale of the problem is not small. Large longitudinal studies consistently find that risk of clinically significant mood symptoms rises during the menopausal transition. They also find that most women do not experience them, which matters just as much to say. UK Biobank data from 128,294 women found a 52% increased incidence of psychiatric disorders during perimenopause compared with the late reproductive stage (incidence rate ratio 1.52, 95% CI 1.39-1.67), with the largest effect for mania (RR 2.12) and a significant increase for major depressive disorder (RR 1.30) (Shitomi-Jones et al., Nature Mental Health, 2024).

The SWAN study - the Study of Women's Health Across the Nation, following over 3,000 women across five ethnic groups - found that women were more likely to experience high depressive symptom scores when perimenopausal or postmenopausal than when premenopausal. The authors were careful to add that health and psychosocial factors also raised those odds, and in some cases mattered more than menopausal status. Women are responding to a biological shift that affects brain chemistry, and to the circumstances of their lives. Both are in play.

And yet most women still reach this transition without being warned, without being screened, and without being offered a clinical response that addresses the full picture.

The Neurobiology of Perimenopausal Depression

One of the most important contributions of the FIGO 2026 guidelines is the explicit framing of perimenopausal mood symptoms as neurobiological events. This matters because it changes what the appropriate response is.

17-beta-estradiol, the primary form of oestrogen active during the reproductive years, is a potent neurosteroid. It acts simultaneously on multiple neurotransmitter systems: it upregulates serotonin receptors and increases serotonin availability; it modulates GABA-A receptor sensitivity; and it enhances dopaminergic signalling. When estradiol begins to fluctuate - which can start years before a final menstrual period - these systems are directly destabilised.

Perimenopause is a prolonged period of erratic fluctuation, often more volatile than the eventual hormonal decline of menopause itself. This means the destabilisation of serotonin, GABA, and dopamine activity can be persistent, unpredictable, and repeated over years. The anxiety that feels physical but has no obvious trigger, the irritability that arrives without warning, the anhedonia that makes everything feel flat, the exhaustion that sleep does not fix - these are not signs of psychological weakness. They are the neurological consequences of hormonal instability affecting brain systems that regulate mood, motivation, and nervous system regulation.

Prior Depression History: The Risk Most Women Are Not Told About

Prior psychiatric history is among the strongest predictors of perimenopausal depression, and the guidelines give it real weight. One finding here is among the most replicated and least communicated: across thirteen years of follow-up in the SWAN cohort, 59% of women with any prior history of major depressive disorder experienced another episode during midlife, compared with 28% of women without that history (Bromberger et al., Psychological Medicine, 2015; 443 women).

More than half. Any prior depressive episode - even a single one, even one that resolved fully decades ago, including postnatal depression - elevates risk during this window.

The FIGO guidelines also identify prior premenstrual dysphoric disorder (PMDD), a history of trauma, and high psychosocial stress as additional risk factors, reflecting a pattern of hormonal sensitivity that runs across reproductive life stages.

The clinical implication is direct: women with any of these histories should be proactively informed about this risk window before they enter perimenopause. They should not be waiting until they are already struggling to be told that the window was predictable.

What Treatment Now Looks Like: The FIGO 2026 Recommendations

The most discussed development in the 2026 guidelines is the place they give transdermal estradiol in treating mood symptoms during the menopausal transition. The guidelines note that it has shown good efficacy for mood symptoms and is preferred where there is metabolic or thrombotic risk, and they grade that recommendation at a moderate level rather than a strong one. Antidepressants and psychotherapy remain the front-line treatments. What has changed is that the hormonal driver is named at all, after years of treating perimenopausal mental health with antidepressants alone.

The evidence base is substantial. Gordon and colleagues (2018) found that transdermal estradiol combined with intermittent micronised progesterone prevented the onset of clinically significant depressive symptoms in euthymic perimenopausal and early postmenopausal women - 17.3% of women on hormone therapy developed clinically significant depressive symptoms compared with 32.3% on placebo. Soares and colleagues (2001) found that transdermal estradiol led to a 68% remission rate over 12 weeks in perimenopausal women with confirmed depressive disorder, compared with 20% in the placebo group. Glynne and colleagues (2026), in a retrospective study of 920 women at the UK's largest specialist menopause clinic, found that transdermal oestradiol and testosterone therapy was associated with a 44.6% mean reduction in mood symptoms after an average of 107 days. This was an uncontrolled cohort study, so it shows association rather than cause, and the authors call for prospective trials.

The proposed mechanism is straightforward. Transdermal delivery bypasses first-pass hepatic metabolism, providing steadier physiological estradiol levels to the systemic circulation. Oestradiol interacts with serotonin, dopamine and GABA systems, so steadier levels are thought to mean steadier activity in those systems, though most of the detailed work behind that has been done in animals.

What About Antidepressants?

None of this makes antidepressants obsolete. The guidelines distinguish between mood symptoms of the transition and major depressive disorder meeting diagnostic criteria, and they discuss hormonal, psychological and antidepressant options, including in combination. Which treatment fits which woman is a decision for her own doctor, made with her full history on the table.

What the guidelines challenge is the reflex prescription of antidepressants without any consideration of whether the underlying hormonal biology is being addressed. Treating the symptom without treating the driver is, at best, incomplete.

What Adequate Clinical Care Now Requires

The FIGO 2026 guidelines call for a fundamental shift in standard midlife care. Routine mental health screening, using tools such as the PHQ-9, is now explicitly recommended as part of standard midlife care. This is because perimenopausal mood symptoms frequently present atypically. Irritability, rage, cognitive fog, emotional lability, and sleep disruption are common presentations that can be missed entirely when clinicians are looking only for classic low mood.

The consequences of underrecognised and untreated depression during this transition extend beyond mood: the guidelines cite impacts on cardiovascular health, cognitive function, bone density, relationships, and occupational functioning. The case for proactive screening is systemic.

What this means for individual women: if your mental health is being assessed without any consideration of your hormonal status, and your hormones are being evaluated without any consideration of your mental health, you are not receiving integrated care. If you have a prior history of depression and are approaching perimenopause, and no one has mentioned the risk window ahead, that is a gap in your care. You are entitled to ask for this conversation, and entitled to a clinician who takes the neurobiological evidence seriously.

What Changes When We Understand This Differently

Struggling while believing the struggle points to something fundamentally wrong with you adds its own weight - a sense of weakness, a failure to manage, an inability to cope with what other people seem to handle. Many women I work with carry this weight into the perimenopausal years without any frame of reference for what is actually happening biologically.

What the FIGO 2026 guidelines represent, beyond the clinical recommendations, is a shift in attribution. When depression and anxiety in midlife are recognised as neurobiological events driven by hormonal instability - rather than psychological fragility or life circumstances - the clinical response changes. And when the clinical response changes, so does what women are offered, and what they understand about their own experience.

It matters enormously whether a woman understands that her nervous system is responding to erratic estradiol fluctuations that are directly disrupting her serotonin and GABA systems - or whether she believes she is simply not coping well with the second half of life. The first framing opens the door to informed, targeted treatment. The second closes it and adds shame on top of an already difficult experience.

The 2026 FIGO guidelines represent the strongest international consensus to date on the neurobiological reality of perimenopausal mental health. What they ask of clinicians is proactive screening, integrated assessment, and a treatment response that includes hormonal biology alongside psychological support. What they ask of healthcare systems is that the evidence already in existence stops being withheld from the women it concerns. And what they confirm, for women who have been struggling in silence and wondering why - is that they were right to suspect that what was happening to them was real.

References

1. Bromberger, J. T., Schott, L., Kravitz, H. M., & Joffe, H. (2015). Risk factors for major depression during midlife among a community sample of women with and without prior major depression: Are they the same or different? Psychological Medicine, 45(8), 1653-1664. https://doi.org/10.1017/S0033291714002773
2. Glynne, S., Kamal, A., McColl, L., Newson, L., Reisel, D., Mu, E., Hendriks, O., Saini, P., Gurvich, C., & Kulkarni, J. (2026). Transdermal oestradiol and testosterone therapy for menopausal depression and mood symptoms: Retrospective cohort study. The British Journal of Psychiatry, 228(5), 409-418. https://doi.org/10.1192/bjp.2025.101
3. Gordon, J. L., Rubinow, D. R., Eisenlohr-Moul, T. A., Xia, K., Schmidt, P. J., & Girdler, S. S. (2018). Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: A randomized clinical trial. JAMA Psychiatry, 75(2), 149-157. https://doi.org/10.1001/jamapsychiatry.2017.3998
4. Khadilkar, S., Divakar, H., Benedetto, C., Genazzani, A., Ramos, D., Argale, E., Deshpande, G., Hickey, M., Filho, A. L. D. S., Herrera, E., & Balkrishnan, M. (2026). FIGO best practice recommendations for the mental health of women at menopausal age. International Journal of Gynecology & Obstetrics, 173(2), 588-601. https://doi.org/10.1002/ijgo.70943
5. Shitomi-Jones, L. M., Dolman, C., Jones, I., Kirov, G., Escott-Price, V., Legge, S. E., & Di Florio, A. (2024). Exploration of first onsets of mania, schizophrenia spectrum disorders and major depressive disorder in perimenopause. Nature Mental Health, 2(10), 1161-1168. https://doi.org/10.1038/s44220-024-00292-4
6. Soares, C. N., Almeida, O. P., Joffe, H., & Cohen, L. S. (2001). Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: A double-blind, randomized, placebo-controlled trial. Archives of General Psychiatry, 58(6), 529-534. https://doi.org/10.1001/archpsyc.58.6.529